Skip to content

Skip to secondary menu

Jehovah’s Witnesses


Sickle Cell Disease (Pediatrics)

Prevention of Sickle Cell Crises—Pharmacological Activation of Fetal Hemoglobin in Children and Infants

Pharmacotherapy in sickle cell disease—state of the art and future prospects.

Hankins J, Aygun B.

Source‎: Br J Haematol 2009;145(3):296-308.

Indexed‎: PubMed 19222472

DOI‎: 10.1111/j.1365-2141.2009.07602.x

Long-term hydroxyurea therapy for infants with sickle cell anemia: the HUSOFT extension study.

Hankins JS, Ware RE, Rogers ZR, Wynn LW, Lane PA, Scott JP, Wang WC.

Source‎: Blood 2005;106(7):2269-75.

Indexed‎: PubMed 16172253

The effect of hydroxcarbamide therapy on survival of children with sickle cell disease.

Lobo CL, Pinto JF, Nascimento EM, Moura PG, Cardoso GP, Hankins JS.

Source‎: Br J Haematol 2013;161(6):852-60.

Indexed‎: PubMed 23590693

DOI‎: 10.1111/bjh.12323

Evidence review of hydroxyurea for the prevention of sickle cell complications in low-income countries.

Mulaku M, Opiyo N, Karumbi J, Kitonyi G, Thoithi G, English M.

Source‎: Arch Dis Child 2013;98(11):908-14.

Indexed‎: PubMed 23995076

DOI‎: 10.1136/archdischild-2012-302387

Hydroxyurea for sickle cell disease: a systematic review for efficacy and toxicity in children.

Strouse JJ, Lanzkron S, Beach MC, Haywood C, Park H, Witkop C, Wilson RF, Bass EB, Segal JB.

Source‎: Pediatrics 2008;122(6):1332-42.

Indexed‎: PubMed 19047254

DOI‎: 10.1542/peds.2008-0441

Impact of hydroxyurea on clinical events in the BABY HUG trial.

Thornburg CD, Files BA, Luo Z, Miller ST, Kalpatthi R, Iyer R, Seaman P, Lebensburger J, Alvarez O, Thompson B, Ware RE, Wang WC; BABY HUG Investigators.

Source‎: Blood 2012;120(22):4304-10.

Indexed‎: PubMed 22915643

DOI‎: 10.1182/blood-2012-03-419879

Effect of hydroxyurea on growth in children with sickle cell anemia: results of the HUG-KIDS Study.

Wang WC, Helms RW, Lynn HS, Redding-Lallinger R, Gee BE, Ohene-Frempong K, Smith-Whitley K, Waclawiw MA, Vichinsky EP, Styles LA, Ware RE, Kinney TR.

Source‎: J Pediatr 2002;140(2):225-9.

Indexed‎: PubMed 11865275

Hydroxyurea is associated with lower costs of care of young children with sickle cell anemia.

Wang WC, Oyeku SO, Luo Z, Boulet SL, Miller ST, Casella JF, Fish B, Thompson BW, Grosse SD; BABY HUG Investigators.

Source‎: Pediatrics 2013;132(4):677-83.

Indexed‎: PubMed 23999955

DOI‎: 10.1542/peds.2013-0333

Hydroxycarbamide in very young children with sickle-cell anaemia: a multicentre, randomised, controlled trial (BABY HUG).

Wang WC, Ware RE, Miller ST, Iyer RV, Casella JF, Minniti CP, Rana S, Thornburg CD, Rogers ZR, Kalpatthi RV, Barredo JC, Brown RC, Sarnaik SA, Howard TH, Wynn LW, Kutlar A, Armstrong FD, Files BA, Goldsmith JC, Waclawiw MA, Huang X, Thompson BW; for the BABY HUG investigators.

Source‎: Lancet 2011;377(9778):1663-72.

Indexed‎: PubMed 21571150

DOI‎: 10.1016/S0140-6736(11)60355-3

Hydroxycarbamide versus chronic transfusion for maintenance of transcranial doppler flow velocities in children with sickle cell anaemia-TCD With Transfusions Changing to Hydroxyurea (TWiTCH): a multicentre, open-label, phase 3, non-inferiority trial.

Ware RE, Davis BR, Schultz WH, Brown RC, Aygun B, Sarnaik S, Odame I, Fuh B, George A, Owen W, Luchtman-Jones L, Rogers ZR, Hilliard L, Gauger C, Piccone C, Lee MT, Kwiatkowski JL, Jackson S, Miller ST, Roberts C, Heeney MM, Kalfa TA, Nelson S, Imran H, Nottage K, Alvarez O, Rhodes M, Thompson AA, Rothman JA, Helton KJ, Roberts D, Coleman J, Bonner MJ, Kutlar A, Patel N, Wood J, Piller L, Wei P, Luden J, Mortier NA, Stuber SE, Luban NL, Cohen AR, Pressel S, Adams RJ

Source‎: Lancet 2016;387(10019):661-70.

Indexed‎: PubMed 26670617

DOI‎: 10.1016/S0140-6736(15)01041-7

How I use hydroxyurea to treat young patients with sickle cell anemia.

Ware RE.

Source‎: Blood 2010;115(26):5300-11.

Indexed‎: PubMed 20223921

DOI‎: 10.1182/blood-2009-04-146852

Sustained long-term hematologic efficacy of hydroxyurea at maximum tolerated dose in children with sickle cell disease.

Zimmerman SA, Schultz WH, Davis JS, Pickens CV, Mortier NA, Howard TA, Ware RE.

Source‎: Blood 2004;103(6):2039-45.

Indexed‎: PubMed 14630791

The medical section of is designed as an informational resource primarily for use by clinicians and other health-care professionals. It provides neither medical advice nor treatment recommendations and does not substitute for an appropriately qualified health-care provider. The clinical literature cited is not published by Jehovah’s Witnesses, but it outlines transfusion-alternative strategies that might be considered. It is the responsibility of each qualified health-care provider to maintain awareness of new information, discuss options for care, and assist patients in making choices in accord with their medical condition, wishes, values, and beliefs. Not all listed strategies are appropriate or acceptable to all patients.

Patients: Always seek the advice of your doctor or other qualified health-care provider regarding medical conditions or treatments. Check with a doctor if you suspect you are ill.

The use of this website is governed by its terms of use.